Sanofi axes cancer combo, early next-gen diabetes drug

Sanofi
Sanofi said it was culling a combination therapy of its approved oncology monoclonal antibody (mAb) Libtayo alongside its phase 3 experimental anti-CD38 mAb isatuximab in “advanced malignancies.” (Sanofi)

If you’ve been paying attention this week, you’ve seen that nearly every Big Pharma has been sweeping out dead R&D projects: Sanofi, posting its third-quarter data early this morning, is no different.

In its financial results, the French Big Pharma said it was culling a combination therapy of its approved oncology monoclonal antibody (mAb) Libtayo alongside its phase 3 experimental anti-CD38 mAb isatuximab in “advanced malignancies.” The combo had been axed in prostate and lung cancer tests.

Libtayo already has the green light for lung cancer, a form of skin cancer and myeloma, while isatuximab, developed with biotech Immunogen, is under FDA review for relapsed/refractory multiple myeloma (MM), with a PDUFA falling in April next year.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Sanofi said this was due to "efficacy considerations," but not concerns over safety. According to ClinicalTrials.gov, it is still being tested in relapsed/refractory MM.

It’s also discontinued work on SAR441255, a trigonal GLP1R/GIPR/GCGR that was in a phase 1 for diabetes/obesity.

This mechanism is gaining ground with its rivals, with Lilly last year posting positive midstage data from its GIP/GLP-1 agonist LY3298176, with several others in phase 1 with their GIP/GCGR/GLP-1 agonists, including Novo Nordisk and Hanmi.

Sanofi’s effort was preclinical last year, but, according to its second-quarter report, starting its phase 1 in the summer. Again, it did not say why it had been removed.

In its results today, Sanofi said it was “well on track,” with sales hitting €9.5 billion ($10.6 billion) for the quarter, up around 1% on a reported basis (but down on CER), and R&D spend at €1.36 billion, also down on this time last year.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.